Systemic administration of epothilone B promotes axon regeneration after spinal cord injury
Author(s) -
Jörg Ruschel,
Farida Hellal,
Kevin C. Flynn,
Sebastián Dupraz,
David A. Elliott,
Andrea Tedeschi,
Margaret L. Bates,
Christopher Sliwinski,
Gary A. Brook,
Kristina Dobrindt,
Michael Peitz,
Oliver Brüstle,
Michael D. Norenberg,
Armin Blesch,
Norbert Weidner,
Mary Bartlett Bunge,
John L. Bixby,
Frank Bradke
Publication year - 2015
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.aaa2958
Subject(s) - axon , spinal cord injury , regeneration (biology) , microtubule , spinal cord , central nervous system , neuroscience , medicine , pharmacology , biology , microbiology and biotechnology
Progress toward fixing a broken back? Axon regeneration after a spinal cord injury requires interference with neuronal mechanisms to promote axon extension and early suppression of scar formation. Microtubule stabilization could provide, in principle, a basis for such intervention. Ruschelet al. used animal models of spinal cord injury, time-lapse imaging in vivo, primary neuronal cultures, and behavioral studies to tackle this challenge (see the Perspective by Tran and Silver). They showed that epothilone B, a U.S. Food and Drug Administration–approved microtubule-stabilizing drug that can cross the blood-brain barrier, does promote functional axon regeneration, even after injury.Science , this issue p.347 ; see also p.285
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom